Catalyst Wire Dossier Catalyst Wire Dossier

Survodutide (BI 456906)

survodutide · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Survodutide (BI 456906), covering 2026-03-12 to 2026-03-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity [Phase 1]

See pricing